UK markets closed

Ascletis Pharma Inc. (1672.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
1.060-0.040 (-3.64%)
At close: 04:08PM HKT
Currency in HKD

Valuation measures4

Market cap (intra-day) 1.07B
Enterprise value -1.44B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)18.31
Price/book (mrq)0.42
Enterprise value/revenue 1.97
Enterprise value/EBITDA -1.06

Trading information

Stock price history

Beta (5Y monthly) 0.63
52-week change 3-44.21%
S&P500 52-week change 323.76%
52-week high 32.300
52-week low 31.050
50-day moving average 31.292
200-day moving average 31.635

Share statistics

Avg vol (3-month) 3767.41k
Avg vol (10-day) 3916k
Shares outstanding 51.01B
Implied shares outstanding 61.09B
Float 8189.59M
% held by insiders 171.72%
% held by institutions 12.01%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -255.70%
Operating margin (ttm)-2,260.79%

Management effectiveness

Return on assets (ttm)-7.50%
Return on equity (ttm)-5.93%

Income statement

Revenue (ttm)56.6M
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)-36.40%
Gross profit (ttm)N/A
EBITDA -294.89M
Net income avi to common (ttm)-144.72M
Diluted EPS (ttm)-0.150
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.3B
Total cash per share (mrq)2.17
Total debt (mrq)8.42M
Total debt/equity (mrq)0.36%
Current ratio (mrq)16.58
Book value per share (mrq)2.21

Cash flow statement

Operating cash flow (ttm)-144.16M
Levered free cash flow (ttm)-131.07M